Horizon Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Horizon Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.31M	Sell	40,323 -45,588	-53%	-$2.5M	0.03%	489
2026 Q1	$4.85M	Sell	85,911 -13,770	-14%	-$803K	0.05%	294
2025 Q4	$5.92M	Buy	99,681 +18,143	+22%	+$988K	0.08%	221
2025 Q3	$4.42M	Sell	81,538 -28,574	-26%	-$1.63M	0.06%	260
2025 Q2	$6.05M	Buy	+110,112	New	+$6.48M	0.1%	172
2022 Q4	–	Sell	-5,469	Closed	-$464K	–	535
2022 Q3	$464K	Buy	+5,469	New	+$487K	0.01%	338
2022 Q2	–	Sell	-9,688	Closed	-$747K	–	468
2022 Q1	$747K	Buy	9,688 +23	+0.2%	+$1.92K	0.02%	272
2021 Q4	$854K	Buy	9,665 +606	+7%	+$50K	0.03%	231
2021 Q3	$700K	Sell	9,059 -874	-9%	-$69K	0.02%	262
2021 Q2	$829K	Buy	9,933 +6,924	+230%	+$549K	0.02%	236
2021 Q1	$227K	Sell	3,009 -720	-19%	-$58.8K	0.01%	404
2020 Q4	$327K	Buy	+3,729	New	+$296K	0.37%	71

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Horizon Investments's BMRN Position: Q2 2026 in Review

Horizon Investments reduced its BioMarin Pharmaceuticals (BMRN) stake by 53% in Q2 2026, selling an estimated $2.5M and leaving 40,323 shares worth $2.31M. The position accounts for 0.03% of the portfolio, ranked #489.

Horizon Investments first reported a position in BMRN in Q4 2020 and has held it in 12 quarters since. The position peaked at $6.05M in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Horizon Investments held 40,323 shares of BioMarin Pharmaceuticals worth $2.31M as of Q2 2026.
Horizon Investments sold 45,588 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.5M.
BioMarin Pharmaceuticals made up 0.03% of Horizon Investments's portfolio in Q2 2026, its #489 holding.
Horizon Investments first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
Horizon Investments's BioMarin Pharmaceuticals position peaked at $6.05M in Q2 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.